We derive models of the effects of periodic, discrete dosing or constant dosing of antibiotics on a bacterial population whose growth is checked by nutrient-limitation and possibly by host defenses. Mathematically rigorous results providing sufficient conditions for treatment success, i.e., the elimination of the bacteria, as well as for treatment failure, are obtained. Our models can exhibit bi-stability where the infectionfree state and an infection-state are locally stable when antibiotic dosing is marginal. In this case, treatment success may occur only for sub-threshold level infections.
Introduction
The pharmacology of antibiotics (or any drug) can be divided into pharmacokinetics and pharmacodynamics. Pharmacokinetics describes the movement of antibiotic into, through and out of the body whereas pharmacodynamics describes the relationship between the concentration of antibiotic, its effect on target bacteria (growth or decay) and factors influencing this relationship [7] . The elimination of drug either by metabolism or excretion is very important since it determines the dosing frequency [1] . One of the important objectives of pharmacokinetics is to decide the optimal dosing frequency of an antibiotic for successful treatment. On the other hand pharmacodynamics describes in detail the relationship between drug concentration and its effects on the bacterial population in order to achieve the maximum removal of bacteria from the host.
Mathematical modeling of the effects of drug treatment has long been used side-by-side with experimental studies [1, 3, 4, 5, 26, 28, 40] However, most mathematical models of the effects of antimicrobial agents on bacterial populations assume that bacteria grow at an exponential rate in the absence of the antimicrobial agent. In that case, one need only determine the pharmacodynamic function for the agent, that is, a mathematical expression for the decline in growth rate resulting from a given concentration of the antimicrobial agent. Once this has been achieved, then the Minimum Inhibitory Concentration (MIC) for the agent is determined as that concentration of the agent at which the growth rate, ψ = ψ(A) vanishes, where A denotes the antibiotic concentration. One can then explore the response of bacteria to various dosing strategies. The expected outcome of this approach is that a dosing strategy that is insufficient to control the population results in its exponential growth while an adequate dosing drives the population to extinction.
It is often found that fast growing bacteria are more susceptible to antibiotic treatment as compared to slow growing ones [3, 6, 22, 27, 29, 38, 39] . A slow growth rate due to the restricted availability of nutrients could be a major contributor toward insensitivity of bacteria to antibiotic. Therefore it is plausible that in some cases the pharmacodynamic function should depend on both the antimicrobial agent and limiting nutrient levels, i.e., ψ = ψ(S, A) where S denotes limiting resource level. It has been noted that bacteria multiply more slowly in an experimental animal than in vitro [4, 6] suggesting nutrient limitation in vivo. Corpet et al [4] introduce pharmacodynamic functions which depend on both limiting nutrient and antimicrobial agent. Cogan [3] does as well in his considerations of persister cells. Cozens et al [6] note that the restricted availability of iron and other nutrients appear to be typical of infection states. Roberts and Stewart [29] construct a mathematical model to explore the possibility that the observed antibiotic tolerance of biofilms is due in part to nutrient limitation reducing bacterial growth and hence killing rates. Even if resource supply rates are relatively constant, one expects significant depletion in local resource levels as a bacterial infection progresses and we expect these changes to play a role in treatment by antimicrobial agents.
We derive simple models of the effects of periodically-administered discrete dosing or constant antimicrobial dosing strategies on a bacterial population whose growth is checked by nutrient-limitation and possibly by host defenses if not by the antimicrobial agent itself. Distinguishing features of our model are the inclusion of nutrient limitation of microbial growth and accounting for removal of antimicrobial agent by association with bacteria. Earlier models such as Austin et al [1] mention nutrient limitation but employ a logistic bacterial growth rate rather than explicitly treating nutrient limitation. Like the model of Austin et al, ours follows the pre-treatment infection dynamics as well as the post-treatment course of bacterial levels.
Most models of antibiotic treatment, e.g. [1] , assume that the pathogen has no effect on antimicrobial concentration; it's concentration at the site of infection is simply an input to the model. In our model, the antibiotic concentration at the site of infection is a dynamic variable with the periodic dosing as input. Standard pharmacokinetics are used but we include a bacteria-dependent drug removal rate, attributable to the association of the drug with bacterial cells, which may be important in some cases.
Mathematically rigorous results are obtained for our models that provide sufficient conditions for treatment success-the elimination of the bacteria, as well as for treatment failure. In the case that antibiotic concentration is assumed to be oscillatory, the MIC, which may depend on resource levels, is no longer the critical parameter. Rather the key parameter is an "invasion eigenvalue" which determines whether bacteria can invade an environment in which antibiotic levels have attained their asymptotic periodic pharmacokinetic regime A * (t): typically, a repeating cycle of exponential decay and recovery following a discrete dose. See Figure 1 . We refer to this regime as the APPR for simplicity. The "invasion eigenvalue", in fact a Floquet exponent, is the average growth rate over a dose-cycle T :
where S 0 is the resource level in the absence of bacteria and A * (t) = A * (t + T ) is the APPR. Although it is often remarked that the amount of time during which A * (t) exceeds the MIC is critical, λ is a much more subtle parameter. The generally nonlinear dependence of ψ on A, means that λ can differ substantially from the growth rate evaluated at the average dose level
In vivo, bacteria usually become established before intervention in the form of antibiotic treatment is administered rather than the other way around where a small inoculum of bacteria is introduced to a pre-established APPR. Therefore, one may be sceptical that the the invasion eigenvalue λ has relevance for treatment. However, in order to eliminate bacteria one must drive down the bacterial population to near extinction where the premise of the invasion eigenvalue approach is satisfied because the state vector approximates the APPR. This suggests, and we prove, that when λ > 0, then bacteria persist and treatment fails because the bacteria-free state is unstable. This is expected since on averaging over a dosing cycle bacteria introduced into the APPR grow when rare. However, λ < 0 implies only local stability of the bacteria-free state. This means that an indeterminately small bacterial population introduced into the APPR is eliminated but one cannot conclude that a larger inoculum is necessarily eliminated. While there are important cases when λ < 0 implies treatment success regardless of initial conditions, in general it does not. In particular, the bacteria-free state can be locally attracting, guaranteeing successful treatment for very small initial bacterial populations, and yet a larger initial population may lead to a stable endemic infection state. We find such bistable dynamics in our model when the antimicrobial dosing is marginal. This dynamic feature is possible when the removal rate of antibiotic depends significantly on bacterial density. In this case, provided sufficient nutrient is present and antibiotic dosing is marginal, high bacterial density can significantly reduce antibiotic concentration thereby reducing its effect. The potential for bistability in antibiotic treatment appears not to have been observed in previous mathematical modeling. It suggests the obvious-early treatment of infection by antibiotics, before bacterial populations have reached high levels, is optimal. The larger message is that antibiotic dosing levels may need to take account of nutrient availability.
Because of the failure of the inequality λ < 0 to guarantee treatment success, we are motivated to find stronger threshold inequalities of the form λ * < 0 where λ < λ * which do guarantee treatment success. We are successful in identifying thresholds λ * expressible entirely in terms of the mean dosing strength, the pharmacodynamic function, and removal rates of antibiotic, resource and bacteria.
The choice of pharmacodynamic function ψ is largely an educated guess even in the case when it can be expected to depend only on antimicrobial agent concentration (ψ = ψ(A)) [1] .
The so-called E max model, based on drug-receptor interaction, is rather standard [25, 15] . In general, a pharmacodynamic function will depend on the particular antimicrobial agent as well as the organism. There appears to be no well-developed pharmacodynamic theory which includes both nutrient and antibiotic. Undoubtedly, there are many possibilities depending on whether or not the two act independently or not. Cogan [3] introduces a pharmacodynamic function depending on the product of a function of nutrient and a function of antibiotic. Corpet et al [4] modify the classical Monod growth rate by assuming either the maximum growth rate or the half-saturation constant is influenced by antibiotic concentration. As these functions are based on educated hunches, our modeling study can only be qualitative in nature exploring possible behavior given only qualitative information about the pharmacodynamic function.
It is well-known that bacterial populations are heterogeneous in their susceptibility to antimicrobial agents [3, 15, 26] . Furthermore, many human pathogens have acquired resistance to the antibiotic of choice which has had an important impact on public health. We also formulate a model where the bacterial population is heterogeneous in its response to the antimicrobial agent either due to mutation or the presence or absence of a transmissible plasmid encoding resistance to the antimicrobial agent. Successful treatment requires eradication of both resistant and susceptible populations. This model has potentially two types of disease states: one with only the susceptible population present and one with both susceptible and resistant populations. We are able to give sufficient conditions for successful treatment and sufficient conditions for treatment failure-i.e., the persistence of a bacterial population. In this case, there are two distinct values of λ, λ s for susceptible and λ r for the resistant population. It is important to understand the conditions favoring the establishment of the mixed population of resistant and susceptible types.
Our work appears to be the first to attempt to obtain mathematically rigorous, explicit sufficient conditions for treatment success and for treatment failure in simple, but hopefully not too simple, mathematical models of periodic drug dosing in vitro and in vivo. Our models combine both the pharmacokinetics of the antibiotic and the pharmacodynamics of its effect on a bacterial population in order to study antibiotic treatment. The mathematical theory of persistence plays a major role here as it is used to characterize treatment failure.
In the next section we formulate and analyze models of antibiotic treatment of a bacterial population which is homogeneous in its response to the antimicrobial agent. In the following section, models containing a susceptible and resistant population are developed. Proofs of our results are relegated to an appendix.
Model of Antibiotic Treatment
We first assume an in vitro environment that can be modeled as a chemostat with the added feature that an antibiotic is also input from the external source. Later we will introduce a more general model suitable for in vivo environments. Let S denotes the concentration of nutrient sustaining microbial growth; u denote the density of bacteria; and A denotes the concentration of an antibiotic. If we view the antibiotic as bactericidal, that is as killing bacteria, then the equations take the form
We assume fresh nutrient at constant concentration S 0 is input and A 0 (t) is the concentration of the antibiotic at time t in the input. Parameter γ is the yield constant and f (S) is the growth rate of bacteria at nutrient concentration S. Typically, we take f to be Monod type but our results hold more generally. We require only that the growth(or uptake) function f (S) be monotone increasing in S:
Typically, antibiotics are administered in either a constant dose A 0 (t) ≡ A 0 = constant or periodically A 0 (t) = A 0 (t + T ) ≥ 0 with dosing period T . While our model allows a general non-negative periodic dosing function A 0 (t), in practice it is typically a sequence of discrete doses which might be approximated by:
Parameter d measures the dose, and δ is the Dirac impulse function.
Function g = g(S, A) is the so-called pharmacodynamic function which describes the kill rate or alternatively, the reduction in the growth rate, induced by the antibiotic agent per unit of bacteria. In general, the killing rate depends on the bacteria and the antibiotic used as well as the nutrient levels. Borrowing from E max theory [1] , one choice is
where H > 0 is the Hill exponent, a the half-saturation concentration and f is specific growth rate. In this case the net growth rate is
where α = 0 for antibiotic that kills in proportion to growth rate (if f (S) = mS/a + S) and α > 0 for antibiotic which is partially effective in killing non-growing bacteria. The simplest term commonly used is independent of nutrient levels, namely
which is usually interpreted as kill rate.
Commonly used functions appearing in the literature are described in the following table.
Table1. Pharmacodynamic Functions
Pharmacodynamic function Reference Description
Cooperativity form
We make only qualitative assumptions regarding the pharmacodynamic function g(S, A). It should vanish in the absence of drug and increase with antibiotic concentration:
Furthermore, adding nutrient should not decrease the net bacterial growth rate:
Finally, (1) includes a removal rate of antibiotic due to its association with bacteria, modeled by the term −p(A)u. p might be taken to be Michaelis-Menten or more generally of Hill type, or simply p(A) = cA. As mentioned in the introduction, most pharmacodynamic models do not include such a term. In some cases, it may be reasonable to neglect this term entirely, taking p = 0, if drug removal rate is relatively independent of u. This case is mathematically attractive since it decouples the pharmacokinetics from the rest of the model. We assume that p vanishes with A and is nondecreasing in A:
The chemostat-based model requires considerable modification if we wish to view it as an in vivo model of the application of antibiotic to a tissue in an organism hosting an infectious bacteria. In this setting, the circulating blood may deliver the antibiotic to the infection site and the nutrient may be supplied by the infected tissue or by the blood circulation. For the in vivo interpretation, the assumption of an identical removal rate D for all components is unreasonable. More generally, we consider
is a flux of nutrient into the infected region, possibly supplied by surrounding tissues or the blood, d S is the removal rate of nutrient which might also include uptake by host cells. d A A 0 (t) is now interpreted as flux of antibiotic into the infected region and d A its removal rate, perhaps due to metabolism in the liver and excretion by the kidney. As for (1), an additional antibiotic removal rate −up(A) due to association of drug with bacterial cells is included. In some cases, this term may be neglected if it is small in relation to removal by metabolism and excretion. The removal rate d u for viable bacteria u may include effects of specific or non-specific immune response [1] . We have included an equation for v, the density of nonviable cells as the antibiotic may be bacteriostatic rather than bacteriocidal. However, as this equation is decoupled from the others, we ignore it hereafter.
Prior to antimicrobial treatment A 0 (t) = 0 and A(t) = 0 so the model reduces to slight modification of the classical chemostat model of microbial growth on a single substrate [32] .
there is no need for treatment), the untreated infection steady state is given by
This can be viewed as the pre-treatment state since this state is most likely approximated just prior to treatment.
If the effect of the antibiotic is to inhibit growth and uptake of nutrient then the following equations may be more natural for in vitro environments
where we always assume that the pharmacodynamic function f (S, A) ≥ 0 is monotonically increasing in S and monotonically decreasing in A. The function f (S, A) could be chosen from among the following: [20, 14] Reduce maximum growth rate
Reduce ability of bacteria to use substrate
S a+S [4] Reduce maximum growth rate where α(A) and β(A) are in the units of concentration and time respectively. m denotes the maximum growth rate and a is the Michaelis-Menton(or half-saturation) constant.
The following equations are more appropriate for an in vivo environment.
In our models (2) and (5), we assume the simplest possible pharmacokinetics, introducing only a single drug compartment A, representing the drug at the site of infection. As drug is usually administered orally or intravenously and then must pass through a number of organs and tissues before reaching the site of infection, more realistic models typically include additional compartments for drug levels in these tissues. Such extensions of our models could be included.
Let T denote the length of the dosing period. If g is a continuous T -periodic function then [g] m will denote the mean value of g:
Hereafter, all periodic functions are to be understood to be T -periodic unless otherwise noted.
It is natural to expect the existence of periodic responses to periodic antibiotic dosing; the constant dosing case is included as a special case. We expect two different types. Naturally, there is the "sterile state" or "infection-free state"
with no bacteria present and nutrient levels matching feed level. A * (t) is the unique periodic solution of
(t) may be called the asymptotic pharmacokinetics since every solution of this simple differential equation is asymptotic to it as t becomes large. It has the following properties
The infection-free state may be viewed as the desired target state in the sense that successful treatment must drive the system state to it.
In addition, there may or may not be one or more "disease states" or "infection states" of the form
whereū(t) > 0 and where all components are positive periodic functions. Such states correspond to treatment failure. Our results will focus on the existence, uniqueness and stability of these solutions. The local stability of the sterile state can be determined by the Floquet exponents of the variational equation about E 0 (t). It turns out that two of these are negative; the third, the "invasion exponent" is given by
for system (2) and (5) . In either case, λ depends on the net, time-averaged bacterial growth rate in the asymptotic pharmacokinetic state where S = S 0 and A = A * (t), involving the growth dynamics, the pharmacodynamic function and the bacterial removal rate.
The following theorem states our main result for both (2) and (5). It includes the autonomous case, A 0 = constant, and the in vitro equations (1) and (4) as a special cases.
Theorem 2.1 For systems (2) and (5), the sterile state E 0 (t) is locally asymptotically stable if λ < 0 and unstable if λ > 0. Moreover:
) is globally attracting in the following cases:
(i) for (5) when p = 0 and for (4) if no E u (t) exists.
(ii) for (2) 
Furthermore, at least one infection state E u (t) exists. Assuming λ > 0, the following also hold: (iii) for (4), every solution with u(0) > 0 converges to one of the periodic states E u (t);
if E u (t) is unique, in particular when p = 0, it attracts all solutions with u(0) > 0.
(iv) If A 0 is constant and p = 0 holds, then E u is unique and globally asymptotically stable for (2) and for (5) .
In summary, Theorem 2.1 establishes that the invasion exponent λ, whose sign characterizes the local stability of the sterile state, can provide useful information concerning the global dynamics of the models in certain cases. Treatment failure is guaranteed when λ > 0 in all cases since bacteria can grow when rare. Furthermore, there exists a least one (periodic) infection state E u (t); in general, it may be non-unique and we do not know its stability properties. An important exception is the case of constant dosing and p = 0 where it is globally attracting.
Only in special cases have we shown that the reverse inequality λ < 0 guarantees treatment success, in the sense of bacterial eradication, regardless of initial conditions. Both such cases require that the removal rate of antibiotic be independent of bacterial density (p = 0).
We note that the system (4) is much more mathematically tractable due to a conservation principle common to chemostat models [32] ; the corresponding reduced system has special monotonicity properties.
The left side of Figure 1 depicts periodic dosing of an antibiotic, given every four hours, with a mean value of 0.2. The right side describes the asymptotic pharmacokinetics A Figure 5 . The MIC curve λ = 0 is also plotted, showing that there is only one disease state when concentration of antibiotic is less than the MIC value and zero or two disease states when concentration is more than MIC. Figure 6 shows the surface u = u(S 0 , A 0 ), giving the bacterial density at the infection state E u . A fold in this surface illuminates the information contained in the right side of Figure 5 . Theorem 2.1 does not provide an adequate set of sufficient conditions for treatment success in the general case p = 0. Our next result applies much more generally, providing a threshold condition for treatment success in terms of parameters and functions appearing in the model. It is a special case of a more general result proved in the appendix.
Theorem 2.2 Let
then u(t) → 0 as t → ∞ for every solution of (2) .
The concavity assumption on g is not necessary but it simplifies the statement of the result. It is satisfied for many of the functions commonly used including the E max model with exponent one. Analogous results can be proved for (5). Assumption (6) is a mild one as c can be taken to be sup{p(A)/A : 0 < A ≤ max t A 0 (t)} so long as p is differentiable at A = 0. Note that the expression on the left in (7), which exceeds λ, depends only on the supplied antibiotic level.
Treatment of Susceptible and Resistant Bacteria
Bacteria may acquire resistance to an antibiotic via spontaneous mutation or the acquisition of new genetic material by transduction, transformation or conjugation. Transduction is the process by which bacterial DNA is moved from one bacterium to another by a virus. Transformation is a process where pieces of DNA in the exterior environment are taken up by the bacteria. Conjugation is the transfer of genetic material between bacteria through cell-to-cell contact and it is thought to play a significant role in the proliferation of antibiotic resistant pathogens [30, 36] . We consider a bacterial population consisting of two types of cells: a plasmid-free cell which is susceptible to an antibiotic and a plasmid-bearing cell which is partially or totally resistant to the antibiotic due to a resistance gene encoded by the plasmid. Hereafter we refer to the cell types as resistant and susceptible. We assume that the resistant, plasmid-bearing cell may transfer a copy of the plasmid to a susceptible, plasmid-free cell via conjugation. Furthermore, a plasmid-bearing cell may miss-segregate plasmid at cell division with probability q resulting in one daughter cell receiving no plasmid and hence becoming susceptible. Our model takes the form:
For simplicity, we assume both cells types have the same growth yield and removal rate and remove antibiotic similarly. We expect that resistant cells grow no faster than susceptible ones and, of course, are at least partially resistant to antibiotic:
Such a cost of plasmid carriage is well documented in the literature, see Lenski [21] although it may decline over many generations due to the effects of natural selection as observed by Dahlberg and Chao [8] .
Horizontal transmission of the plasmid between the two sub-populations is assumed to occur at a rate proportional to the product of their densities: µuu + .
Our model equations (8) are based on the plasmid model of Stephanopoulus and Lapidus [35] . See also Hsu et. al. [11, 12, 13, 14] for a similar modeling of segregative loss in their model of competition between plasmid-bearing and plasmid-free organisms in selective media and [17, 18] for plasmid transfer in biofilms.
Removing the antibiotic from the model results in the "pre-treatment model"
which is studied in detail in [18] (9) has another pretreatment state (S,ũ,ũ + ) consisting of both susceptible and resistant bacteria. Appropriate initial conditions for the post-treatment system (8) are expected to be near the stable equilibrium of the pre-treatment system (9) .
If the antibiotic inhibits the growth and uptake of the nutrient then the following equations may be more appropriate
The periodic solutions of (8) and (10) include the "sterile state" 
E u (t) = (S(t),Ā(t),ū(t), 0)
and infection states with susceptible and resistant organisms of the form
where all components are positive periodic functions. Such infection states need not be unique. Note that if u + (0) = 0 then u + (t) = 0 for all t and this case is discussed in the previous section. Therefore we assume that u(0) > 0 and u + (0) > 0.
As in the previous section, the local stability of the sterile state can be determined by Floquet exponents of the variational equation associated with the periodic solution E 0 (t). Two of these, −d S , −d A are negative; the third and the fourth are the invasion exponents for susceptible and resistant organisms:
for system (8) and (10) .
The counterpart to Theorem 2.1 for treatment of susceptible and resistant populations is the following result. (8) and (10) , the sterile state E 0 (t) is locally asymptotically stable if both λ < 0 and λ + < 0 and unstable if either λ > 0 or λ + > 0. Moreover: (a) If λ < 0, A 0 is constant, and p = 0, then E 0 is globally attracting for (8) when (8) and (10) .
Theorem 3.1 describes the extent to which we have been able to link the local stability properties of the sterile state, as determined by the sign of the invasion exponents λ and λ + , to the global dynamics of the models. In the case of non-constant, periodic dosing, the disease-free state is only locally stable when both λ < 0 and λ + < 0. This means treatment success is only guaranteed for indeterminately small infections. On the other hand, treatment failure is guaranteed when either λ > 0 or λ + > 0, in which case there exists at least one periodic disease state E u (t) or E u * (t). Special attention is focused on the case p = 0 with λ < 0 and λ + > 0 where the resistant, but not the susceptible, strain can invade the sterile state. Of course, treatment failure occurs, both resistant and susceptible organisms persist, and there is a periodic disease state E u * with both resistant and susceptible populations.
More information is available for the constant dosing case. In particular, global stability of the disease-free state holds under certain conditions when λ < 0 and p = 0. If λ > 0 and p = 0, then E u exists and is unique and its stability is determined by whether or not u + can successfully invade it, as determined by the sign of λ + . If the latter is positive then both resistant and susceptible bacteria persist and there is a corresponding steady state with both present.
Our simulation in this section involve only (8) 
Then u(t) + u + (t) → 0 as t → ∞ for every solution of (8) .
Observe that λ * appearing in (12) depends on the (larger) specific growth rate of susceptible bacteria and the (smaller) pharmacodynamic function of resistant bacteria.
Appendices
Proofs of our results are provided in these appendices. The proof of Theorem (2.1) is given in Appendix 1, Theorem 3.1 in Appendix 2, and Theorem (2.2) and Theorem (3.2) are proved in Appendix 3.
Appendix 1
We prove results for (2); similar arguments apply to (4) . Some of part (b) of theorem (2.1) holds for (4) only and so we prove that part only for (4) .
Before proving the main result, we prove the following lemmas for (2) . The first is standard so we omit its proof.
Lemma 4.1 The nonnegative cone R

+ is positively invariant for (2).
Lemma 4.2 All nonnegative solutions of (2) are ultimately uniformly bounded in forward time, and thus they exists for all positive time. Moreover, the system (2) is dissipative in R 3 +
Proof: Multiplying the first equation of (2) by γ and adding to third equation, using a new variable z = γS + u, we arrive at the differential inequality:
This implies
Thus for any initial condition in R
Now, from the second equation we have
which implies that A is ultimately bounded by M 1 = max
These inequalities prove that (2) is dissipative. , applying corollary 2.4(a) of [37] to the S equation of (2)
which gives a contradiction due to the choice of η.
Note that for f (S) = m S a+S
, the value of η is, η =
.
Lemma 4.4 There is a constant θ > 0, independent of initial data, such that A ∞ ≥ θ for all solutions A(t), where θ is a unique, nonzero, root of the equation d S γS
Proof: For any fixed a 1 , the equation 
, applying corollary 2.4(a) of [37] to the A equation of (2)
which gives a contradiction due to the choice of θ.
Proof of Theorem (2.1): (a) The local stability of E 0 (t) can be determined by the Floquet exponents of the variational equation. The variational equation corresponding to E 0 (t) of (2) is:
A computation yields the fundamental matrix Φ(t)
Note that the entries denoting "." play no role in the stability of E 0 (t). Evaluating Φ(t) at t = T , we obtain the multipliers e
In order to prove global stability we first consider the case when
i.e., S(t) is non-increasing for all t ≥ 0. Since S is bounded from below, so it approaches to a limit, denote lim
, then lim t→∞ S (t) = 0 because the lim t→∞ S(t) exists. Then lim t→∞ u(t) exists and lim
. 
, we conclude that there exists a t 0 such that A(t) ≤ A * (t) + for t > t 0 and where > 0 is chosen above. From the u equation of (2) we have [37] . From the inequality
. Let > 0 and take t large so that u
(because lim t→∞ u(t) = 0). Applying Corollary 2.4(a) of [37] to the S equation in (2) . This implies that E 0 (t) is globally asymptotically stable for (2) .
Part (b) We apply theorem (4.1) of [16] . Using the notation, we set
. We want to show that there exists > 0 such that lim inf
Given that (i) X is compact metric space.
(ii) P : X → X is continuous map.
In our case M = E 0 (0), since the omega limit set of solutions starting in X 2 is E 0 (0) where
. We want to show that
In order to show that M is isolated in X we will apply the following theorem 2.3 of [24] . Let V be the neighborhood given by this theorem. Assume that there exists an invariant setK such that
SinceK is positively invariant, all solutions that begin inK stay inK and so in V for positive time. ThusK ⊂ W s (E 1 ). SinceK is negatively invariant, all solutions that begin inK stay inK and so in V for negative time.
For the existence of a positive periodic solution, we assume that X 1 is a convex and relatively open subset in X. The map P satisfies the following conditions (i) P : X → X is point dissipative (since all the positive trajectories eventually lie in a bounded set);
(ii) P is compact (since P is continuous in R
+3
);
(iii) P is uniformly persistent with respect to (X 1 , X 2 ).
The existence of a positive T periodic solution follows directly by theorem 1.3.6 of [41] . For (4), it follows from theorem 4.2 of [32] , every solution with u(0) > 0 converges to one of these states.
If p(A) = 0 and
has concave nonlinearities. By theorem 3.1 of [33] and lemma 2.7 of [11] , if λ > 0, every solution with u(0) > 0 converges to E u (t). If A 0 is constant, p = 0 and λ > 0. Then, a unique E u state can be obtained by setting the right side of (2) equal to zero and then solving for a none-zero S, A, and u. Then
gives a uniqueū such that G(ū) = 0. Thus in this case E u is unique. If λ < 0 then there does not exist aS such that F (S) = 0. The local stability of E u is proved in the next theorem. For the global stability of E u , we consider the limiting system
We apply the Dulac criterion with the auxiliary function g(S, u) = 1 u to (15) and find that
Hence the above system (15) does not have any periodic solution. This together with Poincare-Bendixson theoem implies the global stability of (15) . For the global stability of (2) we use the theorem (F.1) of [32] . Since all the hypotheses of the theorem (F.1) are satisfied, see [18] , so we conclude that E u is globally asymptotically stable.
Proof of Theorem 3.1: (a) The local stability of E 0 (t) can be determined by the Floquet exponents of the variational equation. The variational equation corresponding to E 0 (t) of (8) is:
, A * (t)). Note thatthe entries denoting "." play no role in the stability of E 0 (t). A computation yields the fundamental matrix Φ(t)
Evaluating Φ(t) at t = T , we obtain the multipliers e
and From the u and u + equations of the system (8)
and this implies that lim sup t→∞ (u(t) + u + (t)) ≤ 0. From the positivity of u and u + , we conclude 
Pick a solution (S(t), A(t), u(t)
, u + (t)) with u + (0) > 0. We suppose that u and u + do not uniformly weak persist and derive a contradiction. We can assume that
where n = max{1, γ} and > 0 is chosen above. From the inequality
. We apply Corollary 2.4(a) of [37] to the S equation of (2)
This implies that there exists a
Pick a solution (S(t), A(t), u(t), u + (t))
. For a large t > max{t 0 , t 1 } (say t 1 ), we have from the u + equation of (8):
By integrating (17) from N T ≥ t 1 to nT , with n > N , we have
which gives a contradiction to (16) for a large enough t. Now we will consider the case when λ > 0. We can pick > 0 (it could be different then above ) such that f (S 
Integrate (18) from N T ≥ t to nT we have: Now, we will prove the uniformly strong persistence of either u or u + . Using the notation, we set X = {(S, A, u, u
This map P satisfies the following
(iii) P has a global attractor.
(iii) holds for P because the map P is compact and point dissipative. By theorem 1.3.3. of [41] , there exists an > 0 independent of initial data such that lim inf 
Here we have used that lim inf t→∞ S(t) ≥ η, by the lemma (4.3). Solving for u ∞ we obtain (8) can be written as
This implies, by using the comparison theorem and the well know result from [9] , that there exists a constant e > 0 such that u 
. By theorem 1.3.3. of [41] , there exists an > 0 independent of initial data such that lim inf n→∞ u + (nT ) > and we conclude that lim inf t→∞ u + (t) > with > 0 not depending on the initial data.
The existence of one periodic solution E u * (t) follows from theorem 1.3.6 of [41] . Part (c) The local stability of E u = (S,Ā,ū, 0) is determined by the eigenvalues of the matrix for all large t. But this leads to the contradiction to x(t) → E u , namely that mu(t) + nu + (t) → ∞ as t → ∞. Thus M 1 is a weak repeller. The argument above together with the fact that E u is locally asymptotically stable relative to the subspace u + = 0 implies that it is an isolated compact invariant set in X. Similar arguments show that M 0 is a weak repeller and an isolated compact invariant set in X. Therefore, Theorem 4.6 in [37] implies our result: there exists > 0 such that lim inf t→∞ d(x(t), X 2 ) > for all x(0) ∈ X 1 , where d(x, X 2 ) is the distance from x to X 2 . . Due to the ugliness of this expression, the reader may wish to substitute B 0 for U in the formulae to follow; the results continue to hold in this case.
Appendix 3
Consider the T -periodic scalar equation
in which u has been set to the constant value u = U . It has a unique T -periodic solution A * (t) = A * (t + T ) and it satisfies First of all we will prove that if λ * < 0 then u(t) → 0 as t → ∞ for every solution of (2).
The following generalizes Theorem 2.1 (a): 
